Quality of Life in Parkinson’s Disease – Patient, Clinical and Research Perspectives

Abstract

Parkinson's disease (PD) has a severely negative impact on the quality of life (QoL) of patients and their caregivers. Health-related QoL (HRQoL) is a patient-reported component of QoL that includes physical, mental and social domains and in PD is an increasingly important part of patient monitoring. HRQoL in PD is assessed using a range of different generic (e.g. Short Form-36) and PD-specific (e.g. 39-item Parkinson's Disease Questionnaire) instruments/questionnaires. It is important that HRQoL is regularly determined in patients with PD to identify determinants of their HRQoL deterioration and appropriately manage them. The perspectives of PD patients, clinicians and researchers, however, can be different. In PD, motor symptoms such as slowness or tremor are the most visible manifestations of the disease and these tend to be concentrated on by doctors. PD patients, however, are likely to also have a range of non-motor symptoms such as nocturia, urinary frequency, fatigue, drooling and forgetfulness, which can be more troubling than motor symptoms. These can increase distress and social isolation but are often unreported or overlooked. In addition, morning akinesia and wearing-off phenomena may cause additional difficulty. However, these symptoms and patient concerns can be readily identified using simple HRQoL measures. The management of PD should therefore take into account patient, clinical and research perspectives of HRQoL in order to recognise and adequately address the consequences of motor and non-motor symptoms in PD.

First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers

“…Parkinson's disease is a neurodegenerative disorder that manifests a spectrum of motor, psychiatric, cognitive, sleep, and autonomic signs and symptoms. The key underlying motor manifestation is caused by a slow and progressive degeneration of dopamine‐producing neurons in the substantia nigra . Parkinson's disease affects 7 to 10 million persons worldwide, making it the second most prevalent neurodegenerative disorder after Alzheimer's disease .…”

Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer

“…Quality of life (QoL) measures are patient reported outcomes that attempt to measure physical, mental and social wellbeing that can either be related to general health or disease specific depending on the instrument. There are many generic and PD specific tools available although the most common QoL scale used in clinical trials of PD is the Parkinson's Disease Questionnaire (PDQ-39) which captures the impact of both motor and non-motor symptoms on quality of life [53]. The impact of PD on QoL has been reviewed by others.…”

“…The impact of PD on QoL has been reviewed by others. In summary, PD has a profound impact on quality of life, has been shown to correlate with disease severity and has been useful at determining the impact of symptomatic therapy on patients in early as well as late disease [53,54].…”

Evaluation of Tyrosinase Producing Indigenous Bacterial Strains With Reference to Their Efficacy In L-Dopa Production

“…Parkinson's disease affects approximately 1.5 million people worldwide and the cost of the treatment is more than 14 billion a year according to research published in Movement disorder 2014 [2]. This disease is caused due to insufficiency of the neurotransmitter dopamine [3].…”